Previous Article | Next Article 
Infection and Immunity, December 2001, p. 7550-7558, Vol. 69, No. 12
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.12.7550-7558.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Protective Killed Leptospira
borgpetersenii Vaccine Induces Potent Th1 Immunity Comprising
Responses by CD4 and 
T Lymphocytes
Brian M.
Naiman,1
David
Alt,2
Carole A.
Bolin,3
Richard
Zuerner,2 and
Cynthia L.
Baldwin1,*
Department of Veterinary and Animal Sciences,
University of Massachusetts, Amherst, Massachusetts
010031; Bacterial Diseases of Livestock
Research Unit, National Animal Disease Center, USDA Agricultural
Research Service, Ames, Iowa 500102; and
Department of Pathobiology and Diagnostic Investigation,
Michigan State University, East Lansing, Michigan
488243
Received 14 May 2001/Accepted 20 September 2001
 |
ABSTRACT |
Leptospira borgpetersenii serovar hardjo is the most
common cause of bovine leptospirosis and also causes zoonotic
infections of humans. A protective killed vaccine against serovar
hardjo was shown to induce strong antigen-specific proliferative
responses by peripheral blood mononuclear cells (PBMC) from vaccinated
cattle by 2 months after the first dose of vaccine. This response was absent from nonvaccinated control cattle. The mean response peaked by 2 months after completion of the two-dose vaccination regimen, and
substantial proliferation was measured in in vitro cultures throughout
the 7 months of the study period. Variations in magnitude of the
response occurred among the vaccinated animals, but by 7 months
postvaccination there was a substantial antigen-specific response with
PBMC from all vaccinated animals. Up to one-third of the PBMC from
vaccinated animals produced gamma interferon (IFN-
) after 7 days in
culture with antigen, as ascertained by flow cytometric analysis, and
significant levels of IFN-
were measured in culture supernatants by
enzyme-linked immunosorbent assay. Two-color immunofluorescence
revealed that one-third of the IFN-
-producing cells were 
T
cells, with the remaining cells being CD4+ T cells. The
significance of this study is the very potent Th1-type immune response
induced and sustained following vaccination with a killed bacterial
vaccine adjuvanted with aluminum hydroxide and the involvement of

T cells in the response. Moreover, induction of this Th1-type
cellular immune response is associated with the protection afforded by
the bovine leptospiral vaccine against L. borgpetersenii
serovar hardjo.
 |
INTRODUCTION |
Leptospirosis is a widespread
zoonotic disease that affects virtually all mammals and is an important
cause of reproductive failure and production losses in cattle
throughout the world (14, 16, 18, 19, 23). The most common
cause of leptospirosis among cattle in much of the world is infection
with leptospires belonging to Leptospira
borgpetersenii serovar hardjo. Cattle are the maintenance
host for serovar hardjo and are responsible for the shed and spread of
this pathogen in nature (18). Zoonotic infections of
humans with serovar hardjo represent a significant public health
problem (29). Two serologically indistinguishable but
genetically distinct types of serovar hardjo have been identified. Leptospira interrogans serovar hardjo (type hardjoprajitno)
is isolated primarily from cattle in the United Kingdom
(17), while L. borgpetersenii serovar hardjo
(type hardjo-bovis) is common in cattle populations throughout the
world (17, 42).
Leptospiral vaccines used in cattle in the United States are
inactivated whole-cell vaccines containing L. interrogans
serovars hardjo (type hardjoprajitno), canicola, pomona, and
icterohaemorrhagiae and L. kirschneri serovar grippotyphosa
(21). These pentavalent vaccines provide adequate
protection against disease caused by each of the serovars in the
vaccine except serovar hardjo. That is, they failed to prevent
abortion, stillbirth, and vertical transmission of infection when
vaccinated cows were challenged with L. borgpetersenii
serovar hardjo during pregnancy, and the infection rates for control
and vaccinated cattle did not differ (7). Attempts to
improve the protection against L. borgpetersenii serovar
hardjo by including L. borgpetersenii serovar hardjo in a
pentavalent vaccine (8) or by increasing the quantity of serovar hardjo antigen in a monovalent serovar hardjo vaccine (6) failed. In contrast to these results, recent studies
by Bolin et al. (4, 5) and Ellis et al. (15)
evaluating serovar hardjo monovalent vaccines formulated with a field
isolate of L. borgpetersenii serovar hardjo and another
formulated with L. interrogans serovar hardjo found that
these vaccines prevented infection and tissue colonization following
challenge with L. borgpetersenii serovar hardjo strains from
the United States or Europe. Laboratory and field studies have shown
that these vaccines decrease the incidence of infection, duration, and
intensity of urinary shedding and the incidence of human leptospirosis
in persons in contact with cattle (1, 28-30). The ability
of these vaccines to protect against serovar hardjo may reflect
differences in the serovar hardjo isolates used in the protective
monovalent vaccines or the culture conditions used for preparing the
vaccine bacteria. Such differences may affect the quality or type of
immune response induced.
Because protective immunity to leptospirosis is serovar specific it was
formerly believed to be almost exclusively humoral (18).
While antibodies against leptospiral lipopolysaccharides (LPS) give
passive protection in some animal models (26, 31), cattle
vaccinated against serovar hardjo with pentavalent vaccines are
vulnerable to infection with serovar hardjo despite the presence of
high titers of anti-LPS antibody (6, 8). These studies were the first indicators that anti-LPS antibody was not sufficient for
protection of cattle against serovar hardjo and evoked a reexamination of the paradigm that protective immunity is primarily humoral. Ellis et
al. recently showed that peripheral blood mononuclear cells (PBMC) from
cattle vaccinated with an L. interrogans serovar hardjo
vaccine that provides protection against serovar hardjo proliferated in
vitro in response to hardjo antigens (15). Thus, it has
been suggested that a cell-mediated immune response to serovar hardjo
may be necessary for protection and, therefore, a protective vaccine
would be expected to stimulate this type of immune response
(18). The purpose of this study was to evaluate the
cellular immune response induced by a protective monovalent serovar
hardjo vaccine.
 |
MATERIALS AND METHODS |
Animals and vaccination.
Thirty-two 12- to 15-month-old
heifers that lacked detectable serum antibodies against serovar hardjo
as determined by the microscopic agglutination test (12)
were used. Cattle were housed at the National Animal Disease Center in
Ames, Iowa, and were divided into two groups: nonvaccinated control
cattle (n = 11) and cattle vaccinated with a protective
commercial monovalent serovar hardjo vaccine, Spirovac (CSL Ltd.,
Parkville, Victoria, Australia) (n = 21). Spirovac is a
killed whole-cell vaccine formulated with a bovine isolate of L. borgpetersenii serovar hardjo and aluminum hydroxide. Two 2-ml
doses of Spirovac were administered subcutaneously 4 weeks apart in the
lateral aspect of the neck. All animal use complied with the relevant
federal guidelines and institutional policies and was approved by
Institutional Animal Care and Use Committee and was conducted in
facilities approved by Association for Assessment and Accreditation of
Laboratory Animal Care.
Collection of blood for analysis.
Blood samples were
collected from vaccinated and nonvaccinated control cattle prior to the
administration of the first dose of vaccine (month 0), at the time of
administration of the second dose of vaccine (month 1), and at the
monthly intervals indicated thereafter.
Culture of lymphocytes
Blood was collected
from jugular veins of cattle directly into anticoagulant and shipped by
overnight courier mail arriving approximately 24 h after
collection for processing. PBMC were isolated from blood by
Ficoll-Paque Plus (Pharmacia, Piscataway, N.J.) density gradients
following typical methods (20). PBMC were washed three
times with Hanks' balanced salt solution with heparin at 0.5 U/ml,
following which they were suspended in RPMI 1640 medium (Gibco-BRL,
Rockville, Md.) containing 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 50 µM 2-mercaptoethanol, and 10 µg of
gentamicin per ml (complete RPMI; cRPMI). For the proliferation assays,
5 × 105 PBMC were aliquoted into 96-well flat-bottom
microtiter plates along with cRPMI only, concanavalin A (ConA) at a
final concentration of 1 µg/ml, or serovar hardjo antigen sonicate
(antigen was sonicated whole cells from L.
borgpetersenii serovar hardjo-bovis clone RZ33) at a final
concentration of 0.5 µg of protein/ml in cRPMI so that a total volume
of 0.2 ml/well was achieved. All cultures were set up in quadruplicate.
For cytokine evaluation, 5 × 106 PBMC/well were
aliquoted into a 24-well tissue culture plate, and medium, ConA, or
hardjo antigen was added as for microtiter plates, with a total volume
of 2 ml/well.
Analysis of cell proliferation.
To evaluate proliferation,
cultures were incubated at 37°C with 5% CO2
for 5 days, at which time 0.5 µCi of
[3H]thymidine was added to each well and the
culture was incubated for an additional 12 h. Cultures were then
harvested onto glass fiber filter paper using a cell harvester and
incorporation of [3H]thymidine was determined
by liquid scintillation counting. Results are expressed as counts per
minute (cpm) of [3H]thymidine incorporated into DNA.
Cytokine evaluation by ELISA.
PBMC cultures as described
above were incubated for 5 days except at month 6, when the incubation
was extended to 7 days. At the end of the culture period, PBMC were
resuspended and allowed to settle, and supernatants were collected.
Gamma interferon (IFN-
) was measured in culture supernatants by
enzyme-linked immunosorbent assay (ELISA) using a commercial kit
(Biosource, Camarillo, Calif.) and a Dynex plate reader set to a
wavelength of 450 nm.
Flow cytometry.
To evaluate production of IFN-
by flow
cytometry, cultured cells were restimulated during the last 4 h by
addition of phorbol myristate acetate (PMA) and ionomycin (at a final
concentration of 0.5 µg/ml each) and monensin (final concentration, 2 µM) to facilitate accumulation of detectable amounts of IFN-
inside the cell. After restimulation, cells were stained by indirect immunofluorescence for surface markers to assess T-cell subpopulations using monoclonal antibody (MAb) interleukin A12 (IL-A12) to identify CD4 (3), MAb MMCA837G to identify CD8 (Serotec,
United Kingdom), and MAb GB21A to identify the
chain of the

T-cell receptor (TCR) (VMRD, Pullman, Wash.). This was followed
by goat anti-mouse fluorescein-conjugated isotype-specific secondary
antibody (Southern Biotech, Birmingham, Ala.). Cells were washed and
fixed with 1% paraformaldehyde for 10 min at room temperature. For
intracellular staining, the cells were then permeabilized by incubating
at 4°C overnight in a solution of 20% horse serum, 0.1% saponin,
and 0.1% sodium azide in phosphate-buffered saline (PBS).
Intracellular immunostaining was performed using anti-bovine IFN-
MAb 7B6 or anti-bovine IL-4 MAb 1048, both kindly provided by J.-J.
Letesson (45, 46). Cells were reacted with the
anti-cytokine MAb in a solution of PBS containing 5% horse serum,
0.1% saponin, and 0.1% sodium azide for 45 min at 4°C, washed twice
in PBS with 0.1% saponin, and then they were reacted with goat
anti-mouse phycoerythrin-conjugated isotype-specific secondary antibody
(Southern Biotech) for 30 min at 4°C, washed twice, and analyzed by
flow cytometry using a FACS Calibur (Becton Dickinson, Palo Alto,
Calif.). An isotype-matched control antibody for the anticytokine
antibodies was used for intracellular staining in some experiments and
found not to increase background fluorescence.
Purification of 
T cells.

T cells were purified
by magnetic bead sorting. Cells were stained with
anti-WC1+ MAb IL-A29 (11) for 20 min
at 4°C, washed with a solution of PBS containing 2% heat-inactivated
horse serum, and reacted with goat anti-mouse immunoglobulin (IgG) MACS
secondary microbeads (Miltenyi Biotec, Auburn, Calif.). Cells were
purified over a positive separation column (Miltenyi Biotec) and a
sample was assessed by flow cytometry for enrichment. The remaining
cells were cultured with antigen and assessed for proliferation and cytokine production as described above.
Statistical analyses
Responses by PBMC from
vaccinated and nonvaccinated control cattle were compared by using
Student's t test.
 |
RESULTS |
Proliferative response to antigen.
There was a significant
proliferative response by PBMC from vaccinated cattle when cultured
with the L. borgpetersenii serovar hardjo antigen
preparation by 2 months after cattle received the first dose of the
vaccine (Fig. 1A). The response peaked by
2 months after the completion of the two-dose vaccine (i.e., month 3 of
the study) and was sustained throughout the 7-month study period. Only
low levels of spontaneous proliferation occurred in cultures without
antigen (medium controls), and no significant proliferation above
medium controls was ever observed when the PBMC from nonvaccinated
animals were cultured with the antigen preparation (Fig. 1B). The PBMC
from both vaccinated and nonvaccinated cattle had very similar
proliferative responses to the mitogen ConA throughout the study. A
suboptimal concentration of ConA was used to avoid overproliferation
and cell death during the more prolonged culture times required to
measure antigen-specific responses.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 1.
Means and standard errors of proliferation by PBMC from
vaccinated (A) or nonvaccinated (B) cattle, as determined by the
incorporation of [3H]thymidine in response to either
L. borgpetersenii serovar hardjo-bovis antigen, medium,
or a suboptimal concentration of ConA. Cattle were vaccinated with the
first dose administered at month 0 and the second dose at month 1.
|
|
Variation in responses among vaccinated cattle
Variation in the proliferative responses by PBMC from individual
vaccinated cattle to the antigen was apparent by 3 months after the
first dose of vaccine (Fig. 2). PBMC from
5 of 19 animals exhibited proliferative responses to the antigen that
were at least 3 standard errors less than the mean of all the
vaccinated cattle (i.e.,
49,000 cpm). However, the proliferative
responses of PBMC from these animals continued to increase with time
(Fig. 3) and by month 7 the magnitudes of
the individual responses were similar to the mean of all the vaccinated
cattle.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 2.
Proliferation by PBMC from individual vaccinated animals
in response to culture with either L. borgpetersenii
serovar hardjo-bovis antigen or medium at 3 months after the first dose
of vaccine. The means of incorporated [3H]thymidine from
quadruplicate wells are shown with the standard errors.
|
|

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 3.
The proliferation of PBMC from five vaccinated animals
with low responses at 3 months after the first dose of the vaccine in
response to L. borgpetersenii serovar hardjo-bovis
antigen. The means for quadruplicate cultures are shown with the
standard error. The dashed line indicates the mean values for the
entire vaccinated group as a reference point.
|
|
Production of IFN-
.
Once PBMC had shown a substantial
proliferative response, IFN-
production was evaluated. PBMC from
vaccinated and nonvaccinated cattle were cultured with and without
antigen and culture supernatants were assessed by ELISA (Fig.
4). Throughout the study, PBMC from vaccinated cattle produced more IFN-
in antigen-stimulated cultures than in medium control cultures. Nonvaccinated cattle produced only
minimal amounts of IFN-
and generally not significantly more in
antigen-stimulated cultures than in medium control cultures. At months
3 and 4, 15 and 20%, respectively, of the supernatants from cultures
of PBMC from vaccinated cattle stimulated with antigen contained a
quantity of IFN-
higher than the sensitive range of the assay. Had
those samples been taken to the endpoint, mean optical density (OD)
values may have been higher for response to antigen. Supernatants in
months 6 and 7 were diluted so that samples could be read within the
sensitive range of the assay.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 4.
The mean and standard error of IFN- produced in PBMC
cultures from vaccinated or nonvaccinated cattle after culture with
leptospira antigen (Ag) or medium (Med). PBMC were evaluated at 3 months (A), 4 months (B), 6 months (C), or 7 months (D). The culture
supernatants were assessed by ELISA, and the units shown are OD units
from an ELISA plate reader using a wavelength of 450 nm. At months 3 and 4, 15 and 20% of the samples, respectively, were beyond the range
of the assay. At months 6 and 7, 18 and 68% of the samples,
respectively, were beyond the range when tested undiluted; however,
dilutions of the supernatants were tested and the OD units were
adjusted according to the dilution. At month 6 only vaccinated cattle
were sampled. An asterisk indicates a response by the vaccinated group
cultured with antigen which is significantly higher than the response
by the nonvaccinated cattle at each time point (P < 0.01).
|
|
PBMC in cultures were also assessed for the percentage of cells
producing IFN-
by flow cytometry. The mean percentage of IFN-
-producing cells in PBMC cultures from vaccinated cattle in
response to antigen was significantly higher than that of nonvaccinated cattle (Fig. 5). The mean percentage of
IFN-
-producing cells from nonvaccinated cattle in response to
antigen was similar to that in cultures without antigen. At month 4, PBMC from a sample of five vaccinated and five nonvaccinated cattle in
antigen-stimulated cultures were stained for intracellular IL-4; none
of the animals tested had IL-4-producing cells as determined by flow
cytometry (data not shown).

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 5.
Mean percentages of IFN- -positive cells from cultures
of PBMC from vaccinated and nonvaccinated cattle. These cells were
restimulated with PMA-ionomycin, permeabilized, and stained for
intracellular IFN- using indirect immunofluorescence and flow
cytometric analysis. The means and standard errors are shown. At month
6, only the vaccinated cattle were sampled. The asterisk indicates a
significant difference in the response to antigen
(P < 0.03).
|
|
Phenotype of IFN-
-producing cells
Two-color
flow cytometric analysis was done to determine the phenotype of
IFN-
+ cells in cultures of PBMC from vaccinated cattle
that were stimulated with antigen at months 5 and 6. An example of the
two-color surface and intracellular immunofluorescence is shown (Fig.
6A). The results from vaccinated animals
indicated that approximately two-thirds of IFN-
+ cells
were within the CD4+ T-cell population while the remaining
one-third were 
T cells (Fig. 6B). A few CD8 T cells were also
shown to be producing IFN-
in the antigen-stimulated cultures, but
the percentage was not greatly higher than the low percentage of
CD8+/IFN-
+ cells detected in PBMC cultures
with medium. That is, in the medium control cultures there were always
a few IFN-
+ cells (<5%) as a result of restimulation
with PMA and ionomycin during the last few hours of culture necessary
to detect intracellular IFN-
(data not shown).

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 6.
Percentages of IFN- -producing cells in PBMC from six
vaccinated animals with high proliferative responses at month 5 after
stimulation with L. borgpetersenii antigen are shown.
The PBMC were cultured for 7 days and restimulated with PMA-ionomycin,
and two-color immunofluorescence was performed and analyzed by flow
cytometry. (A) An example of two-color flow cytometric analysis shown
by dot plot. Detection of IFN- is shown on the y
axis, and either CD4 or  -TCR is shown on the x
axis. Double positives are in the upper right quadrant. (B) Means and
standard errors of results with PBMC from six vaccinated animals. Shown
are the total percentage of IFN- + cells in the cultures
and the percentage of cells double staining for CD4 and IFN- or for
 -TCR and IFN- .
|
|
To further investigate the response of 
T cells to the leptospira
antigen, 
T cells were enriched to 88 and 90% from PBMC by
magnetic bead sorting using cells from two vaccinated animals that had
previously shown significant proliferative responses and IFN-
production in response to antigen. Enriched populations of 
T
cells from both animals proliferated in response to antigen (animal no.
214, 16,260 ± 3,216 cpm [mean ± standard deviation] with antigen and 3,249 ± 445 cpm in medium cultures;
animal no. 223, 6,822 ± 1,730 cpm with antigen and 816 ± 133 cpm in medium cultures). Two-color immunofluorescence revealed that
73.5 and 74.2% of the 
T cells from the two animals were
IFN-
+ in cultures with antigen.
 |
DISCUSSION |
In the last decade it has been shown that a pivotal point in
immune responses is the decision to make either a Th1-type response characterized by T-cell production of IFN-
and a bias of the antibody response towards IgG2 or a Th2 response characterized by
production of IL-4 by T cells and antibodies of the IgE, IgG1, and IgA
isotypes. Like other mammals, cattle have Th1 and Th2 cells
(10). The Th1-type response is a component of
cell-mediated immunity and is generally considered necessary for
resistance to intracellular microbial infections, while a Th2 response
promotes a good humoral response and resistance to extracellular
organisms. Thus, it was of interest to test the hypothesis that
vaccines that protect against the extracellular bacterium L. borgpetersenii serovar hardjo induce cell-mediated immune
responses. The results presented here indicated that the protective
serovar hardjo vaccine did induce a strong, sustained Th1 or
cell-mediated immune response since CD4 T cells from vaccinated cattle
produced IFN-
in response to stimulation by antigen. In a small
pilot study, cattle given a reference vaccine typical of U.S.
pentavalent leptospiral vaccines that fail to protect against hardjo
did not develop such a response (B. M. Naiman, C. L. Baldwin,
and C. A. Bolin, unpublished data). The lymphocyte proliferative
response observed here was similar to that reported by Ellis et al.
using PBMC from cattle vaccinated with another protective serovar
hardjo vaccine (15). Further work will be required to
determine which components of the Th1-type immune response are
responsible for the protection against serovar hardjo. It is possible
that IgG2 antibodies induced by IFN-
may be singularly responsible
for protection.
While the proliferative response peaked quickly in the majority of
vaccinated animals, it was nevertheless sustained throughout the 7 months of the study. Even the response by the initially low responders
continued to rise throughout the study period, and there were no
differences in the phenotypes of cells that responded to antigen from
the low responders and from the other vaccinated animals (data not
shown). Why the kinetics of responses were so different in those five
animals is unclear, but we speculate that there may be differences in
the way the vaccine was deposited in vivo so that a slower release of
antigen occurred in these animals. Some variation during the study
period may have reflected a general decrease in proliferative responses
since it has been shown that proliferation by bovine PBMC to mitogens
decreases during winter months in the Northern hemisphere
(39). The seventh month of this study was mid-January. The
apparent seasonal effect was evident, for instance, in the responses to
ConA with cells from both groups of cattle.
With a few exceptions, immunization with killed or inactivated bacteria
or viruses is not generally associated with induction of a strong
cell-mediated immune response. Thus, it was interesting that the killed
whole-cell vaccine in this study induced such a strong Th1-type immune
response. The response was not a mitogenic response since there was no
significant proliferation in cultures of PBMC from the nonvaccinated
control animals. Aluminum hydroxide, the adjuvant in the vaccine
employed here, has been shown to potentiate either Th1 or Th2 immune
responses (9, 27). Thus, the aluminum hydroxide adjuvant
could facilitate the induction of a Th1 response; however, leptospira
components in the vaccine strain may also be Th1-promoting adjuvants.
For example, it is known that complete Freund's adjuvant which
contains components of inactivated Mycobacterium produces a
Th1 response (48) due in part to the unique lipid trehalose dimycolate in the bacterial cell envelope (37,
47). Other bacterial factors that may possess Th1 adjuvant
properties include muramyl dipeptide (2) and CpG, a
phosphate-containing bacterial DNA sequence. CpG elicits a strong Th1
immune response especially when used in conjunction with an alum
adjuvant (32, 43).
With regard to the subpopulations of T cells that responded to the
antigen in vitro, the lack of CD8+ T-cell
response was expected since the vaccine was killed, and thus,
presentation by major histocompatibility complex class I would be
unlikely. While some adjuvants such as saponin are known to promote
major histocompatibility complex class I presentation (34), this has not been reported for aluminum hydroxide.
We speculate that the few CD8+ T cells that were
producing IFN-
were responding as bystanders to cytokines made by
the other T-cell populations, since we have shown that bovine
CD8+ T cells do proliferate in response to
stimulation with recombinant IL-2 (36). Presumably IL-2
was present in the antigen-stimulated cultures since high levels of
proliferation occurred. 
T cells, however, were a major
population-producing IFN-
in addition to the CD4 T cells. Sorting of
the 
T cells by magnetic beads prior to exposure to antigen
demonstrated that the response by this T-cell subpopulation is a direct
response to antigen rather than a bystander effect in response to
cytokines secreted by other cell types activated in the PBMC cultures.
Interestingly, humans infected with another spirochete, Borrelia
burgdorferi, also have a large proportion of 
T cells that
proliferate specifically to that organism (44). Production
of IFN-
by 
T cells in this system is interesting especially
in light of a recent report indicating that 
T cells from
Mycobacterium bovis-infected cattle proliferated to
mycobacterial antigens but did not produce IFN-
(38).
It may be the IFN-
production by the 
T cells that contributes
to the strong CD4 Th1-type immune response induced by the vaccine since
recent evidence suggests that IFN-
activates CD4 T cells to express
T-bet and differentiate to Th1 cells (40; S. Szabo, personal
communication). It has also been shown that 
T cells can
selectively kill Th2 CD4 T cells through the apoptosis signal generated
by Fas/Fas ligand interaction (25). It will be of
particular interest to identify the components of the vaccine evaluated
here that stimulate 
T cells so effectively since identification
of the 
T-cell-stimulating component may reveal an interesting
type 1-promoting adjuvant. While there is not a great deal known about
the stimulatory ligands for 
T cells, some antigens are derived
from bacteria such as Mycobacteria heat shock protein
(22) and the nonproteinaceous mycobacterial components known as isopentenyl pyrophosphate or TUBag1 to 4 (13,
41).
It has not been conclusively established whether 
T cells are
part of the adaptive or innate arm of the immune system. An early study
found that the proportional representation of 
T cells with
various TCR differed between identical human twins (35),
suggesting that the 
T cell subpopulations expand as a result of
antigenic experience. However, there are few studies of 
T cells
that evaluated a functional definition of memory, e.g., a more rapid
response and/or effective control of a secondary infection. A recent
study showed that people who are sensitized by Mycobacteria
have a population of 
T cells that rapidly proliferate in
response to stimulation with defined mycobacterial components in vitro
(24). In contrast, nonvaccinated people do not have this

T-cell response, suggesting that the vaccine expanded or
sensitized the responsive 
T cells in vivo, as occurred with the
leptospira vaccine used here. Results from a study using mice that have
been vaccinated with the microbial pathogen Listeria monocytogenes by an infection and antibiotic treatment protocol and then challenged with live listeriae show that 
T-cell
responses play a perceptible role in resistance to secondary challenge, although it was less than that of 
T cells and only marginally greater than it was in primary infections (33). The 
T cells in the studies reported here seemed to be responding
specifically as part of an acquired immune response since 
T
cells from nonvaccinated cattle did not produce IFN-
. It is possible
that the participation of 
T cells in the in vitro response
reflected activation in vivo, although no response in medium cultures
was observed. To determine if the 
T-cell response is an adaptive
immune response it will be necessary to determine whether they mature
into a long-lived memory population. It will be of interest to use the
leptospira system evaluated here for assessing this.
 |
ACKNOWLEDGMENTS |
This work was partially funded by a grant from Pfizer, Inc., CSL,
Ltd., and USDA NRI/CGP 00-02293.
We thank J. J. Letesson for providing the anti-IFN-
and IL-4
monoclonal antibodies, Rick Hornsby and Annette Olson for their excellent technical assistance, and Cyril Gay and Bill Ellis for helpful discussions.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Veterinary and Animal Sciences, 410 Paige Laboratory, University of
Massachusetts, Amherst, MA 01003. Phone (413) 545-3167. Fax (413)
545-6326. E-mail: cbaldwin{at}vasci.umass.edu.
Editor:
R. N. Moore
 |
REFERENCES |
| 1.
|
Allen, J. D.,
C. L. Meney, and C. R. Wilks.
1982.
Evaluation of a hardjo-pomona vaccine to prevent leptospiruria in cattle exposed to a natural challenge with Leptospira interrogans serovar hardjo.
Aust. Vet. J.
58:93-96[Medline].
|
| 2.
|
Archambault, D.,
G. Morin, and Y. Elazhary.
1988.
Influence of immunomodulatory agents on bovine humoral and cellular immune responses to parenteral inoculation with bovine rotavirus vaccines.
Vet. Microbiol.
17:323-334[CrossRef][Medline].
|
| 3.
|
Baldwin, C. L.,
A. J. Teale,
J. Naessens,
B. M. Goddeeris,
N. D. MacHugh, and W. I. Morrison.
1986.
Characterization of a subset of bovine T-lymphocytes by monoclonal antibodies and function: similarity to lymphocytes defined by human T4 and murine L3T4.
J. Immunol.
136:4385-4391[Abstract].
|
| 4.
|
Bolin, C. A., and D. P. Alt.
2001.
Use of a monovalent leptospiral vaccine to prevent renal colonization and urinary shedding in cattle exposed to Leptospira borgpetersenii serovar hardjo.
Am. J. Vet. Res.
62:995-1000[CrossRef][Medline].
|
| 5.
|
Bolin, C. A.,
D. P. Alt, and R. L. Zuerner.
2000.
Protection of cattle from renal and genital tract colonization with Leptospira borgpetersenii serovar hardjo.
In
Proceedings of the 21st World Buiatrics Congress. Punte del Este, Uruguay.
|
| 6.
|
Bolin, C. A.,
J. A. Cassells,
R. L. Zuerner, and G. Trueba.
1991.
Effect of vaccination with a monovalent Leptospira interrogans serovar hardjo type hardjo-bovis vaccine on type hardjo-bovis infection of cattle.
Am. J. Vet. Res.
52:1639-1643[Medline].
|
| 7.
|
Bolin, C. A.,
A. B. Thiermann,
A. L. Handsaker, and J. W. Foley.
1989.
Effect of vaccination with a pentavalent leptospiral vaccine on Leptospira interrogans serovar hardjo type hardjo-bovis infection of pregnant cattle.
Am. J. Vet. Res.
50:161-165[Medline].
|
| 8.
|
Bolin, C. A.,
R. L. Zuerner, and G. Trueba.
1989.
Effect of vaccination with a pentavalent leptospiral vaccine containing Leptospira interrogans serovar hardjo type hardjo-bovis on type hardjo-bovis infection of cattle.
Am. J. Vet. Res.
50:2004-2008[Medline].
|
| 9.
|
Brewer, J. M.,
M. Conacher,
C. A. Hunter,
M. Mohrs,
F. Brombacher, and J. Alexander.
1999.
Aluminum hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4 or IL-13-mediated signaling.
J. Immunol.
163:6448-6454[Abstract/Free Full Text].
|
| 10.
|
Brown, W. C.,
V. M. Woods,
C. G. Chitko-McKown,
S. M. Hash, and A. C. Rice-Ficht.
1994.
Interleukin-10 is expressed by bovine type 1 helper, type 2 helper, and unrestricted parasite-specific T-cell clones and inhibits proliferation of all three subsets in an accessory-cell-dependent manner.
Infect. Immun.
62:4697-4708[Abstract/Free Full Text].
|
| 11.
|
Clevers, H.,
N. D. MacHugh,
A. Bensaid,
S. Dunlap,
C. L. Baldwin,
A. Kaushal,
K. Iams,
C. J. Howard, and W. I. Morrison.
1990.
Identification of a bovine surface antigen uniquely expressed on CD4 D8 T cell receptor- + T lymphocytes.
Eur. J. Immunol.
20:809-817[Medline].
|
| 12.
|
Cole, J. R.,
C. R. Sulzer, and A. R. Pursell.
1973.
Improved microtechnique for the leptospiral microscopic agglutination test.
Appl. Microbiol.
25:979-980.
|
| 13.
|
Constant, P.,
Y. Poquet,
M. A. Peyrat,
F. Davodeau,
M. Bonneville, and J. J. Fournie.
1995.
The antituberculous Mycobacterium bovis BCG vaccine is an attenuated mycobacterial producer of phosphorylated nonpeptidic antigens for human  T cells.
Infect. Immun.
63:4628-4633[Abstract].
|
| 14.
|
Ellis, W. A.
1994.
Leptospirosis as a cause of reproductive failure.
Vet. Clin. N. Am. Food Anim. Pract.
10:463-478[Medline].
|
| 15.
|
Ellis, W. A.,
S. W. J. McDowell,
D. P. Mackie,
J. M. Pollock, and M. J. Taylor.
2000.
Immunity to bovine leptospirosis.
In
Proceedings of the 21st World Buiatrics Congress. Punte del Este, Uruguay.
|
| 16.
|
Ellis, W. A.,
J. J. O'Brien,
D. G. Bryson, and D. P. Mackie.
1985.
Bovine leptospirosis: some clinical features of serovar hardjo infection.
Vet. Rec.
117:101-104[Abstract].
|
| 17.
|
Ellis, W. A.,
A. B. Thiermann, and R. B. Marshall.
1986.
Genotypes of Leptospira hardjo and their role in clinical disease, p. 966-970.
In
Proceedings of the 14th World Congress on Diseases of Cattle, Dublin, Ireland.
|
| 18.
|
Faine, S.,
B. Adler,
C. A. Bolin, and P. Perolat.
1999.
Leptospira and leptospirosis, 2nd ed.
MediSci Press, Melbourne, Australia.
|
| 19.
|
Giles, N.,
S. C. Hathaway, and A. E. Stevens.
1983.
Isolation of Leptospira interrogans serovar hardjo from a viable premature calf.
Vet. Rec.
113:174-176[Abstract].
|
| 20.
|
Goddeeris, B. M.,
C. L. Baldwin,
O. ole-MoiYoi, and W. I. Morrison.
1986.
Improved methods for purification and depletion of monocytes from bovine peripheral blood mononuclear cells. Functional evaluation of monocytes in responses to lectins.
J. Immunol. Methods
89:156-173.
|
| 21.
|
Hanson, L. E.,
D. N. Tripathy, and A. H. Killinger.
1972.
Current status of Leptospirosis immunization in swine and cattle.
J. Am. Vet. Med. Assoc.
161:1235-1243[Medline].
|
| 22.
|
Haregewoin, A.,
G. Soman,
R. C. Hom, and R. W. Finberg.
1989.
Human  T cells respond to mycobacterial heat-shock protein.
Nature
340:309-312[CrossRef][Medline].
|
| 23.
|
Heath, S. E., and R. Johnson.
1994.
Leptospirosis.
J. Am. Vet. Med. Assoc.
205:1518-1523[Medline].
|
| 24.
|
Hoft, D. F.,
R. M Brown, and S. T. Roodman.
1998.
Bacille Calmette-Guerin vaccination enhances human  T cell responsiveness to mycobacteria suggestive of a memory-like phenotype.
J. Immunol.
160:1045-1054.
|
| 25.
|
Huber, S. A.,
R. C. Budd,
K. Rossner, and M. K. Newell.
1999.
Apoptosis in coxsackievirus B3-induced myocarditis and dilated cardiomyopathy.
Ann. N. Y. Acad. Sci.
887:181-190[Medline].
|
| 26.
|
Jost, B. H.,
B. Adler,
T. Vihn, and S. Faine.
1986.
A monoclonal antibody reacting with a determinant on leptospiral lipopolysaccharide protects guinea pigs against leptospirosis.
J. Med. Microbiol.
22:269-275[Medline].
|
| 27.
|
Krishnan, L.,
C. J. Dicaire,
G. B. Patel, and G. D. Sprott.
2000.
Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: comparison to conventional liposomes and alum.
Infect. Immun.
68:54-63[Abstract/Free Full Text].
|
| 28.
|
Mackintosh, C. G.,
R. B. Marshall, and E. S. Broughton.
1980.
The use of hardjo-pomona vaccine to prevent leptospiruria in cattle exposed to natural challenge with Leptospira interrogans serovar hardjo.
N. Z. Vet. J.
28:174-177[Medline].
|
| 29.
|
Marshall, R. B.
1987.
A nationwide experiment to control human leptospirosis by vaccinating dairy cattle.
Isr. J. Med. Sci.
43:271-276.
|
| 30.
|
Marshall, R. B.,
E. S. Broughton, and J. S. Hellstrom.
1979.
Protection of cattle against natural challenge with Leptospira interrogans serovar hardjo using hardjo-pomona vaccine.
N. Z. Vet. J.
27:114-116[Medline].
|
| 31.
|
Masuzawa, T.,
R. Nakamura,
Y. Hashiguchi,
T. Shimizu,
Y. Iwamoto,
T. Morita, and Y. Yanagihara.
1990.
Immunological reactivity and passive protective activity of monoclonal antibodies against protective antigen (PAg) of Leptospira interrogans serovar lai.
Zentbl. Bakteriol. Reihe A
272:328-336.
|
| 32.
|
McCluskie, M. J.,
R. D. Weeratna, and H. L. Davis.
2000.
Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution.
Mol. Med.
6:867-877[Medline].
|
| 33.
|
Mombaerts, P.,
J. Arnoldi,
F. Russ,
S. Tonegawa, and S. H. E. Kaufman.
1993.
Different roles of  and  T cells in immunity against an intracellular bacterial pathogen.
Nature
365:53-56[CrossRef][Medline].
|
| 34.
|
Newman, M. J.,
J.-Y. Wu,
B. H. Gardner,
K. J. Munroe,
D. Leombruno,
J. Recchia,
C. R. Kensil, and R. T. Coughlin.
1992.
Saponin adjuvant induction of ovalbumin-specific CD8 cytotoxic T lymphocyte responses.
J. Immunol.
148:2357-2362[Abstract].
|
| 35.
|
Parker, C. M.,
K. V. Groh,
H. Band,
S. A. Porcelli,
C. Morita,
M. Fabbi,
D. Glass,
J. L. Strominger, and M. B. Brenner.
1990.
Evidence for extrathymic changes in the T cell receptor  repertoire.
J. Exp. Med.
171:1597-1612[Abstract/Free Full Text].
|
| 36.
|
Sathiyaseelan, T., and C. L. Baldwin.
2000.
Evaluation of cell replication by bovine T cells in polyclonally activated cultures using carboxyfluorescein succinimidyl ester (CFSE) loading and flow cytometric analysis.
Res. Vet. Sci.
69:275-281[CrossRef][Medline].
|
| 37.
|
Singh, I. G.,
R. Mukherjee,
G. P. Talwar, and S. H. Kaufmann.
1992.
In vitro characterization of T cells from Mycobacterium w-vaccinated mice.
Infect. Immun.
60:257-263[Abstract/Free Full Text].
|
| 38.
|
Smyth, A. J.,
M. D. Welsh,
R. M. Girvin, and J. M. Pollock.
2001.
In vitro responsiveness of  T cells from Mycobacterium bovis-infected cattle to mycobacterial antigen: predominant involvement of WC1+ cells.
Infect. Immun.
69:89-96[Abstract/Free Full Text].
|
| 39.
|
Soper, F. F.,
C. C. Muscoplat, and D. W. Johnson.
1978.
In vitro stimulation of bovine peripheral blood lymphocytes: analysis of variation of lymphocyte blastogenic response in normal dairy cattle.
Am. J. Vet. Res.
39:1039-1042[Medline].
|
| 40.
|
Szabo, S. J.,
S. T. Kim,
G. L. Costa,
X. Zhang,
C. G. Fathman, and L. H. Glimcher.
2000.
A novel transcription factor, T-bet, directs Th1 lineage commitment.
Cell
100:655-669[CrossRef][Medline].
|
| 41.
|
Tanaka, Y.,
C. T. Morita,
Y. Tanaka,
E. Nieves,
M. B. Brenner, and B. R. Bloom.
1995.
Natural and synthetic non-peptide antigens recognized by human  T cells.
Nature
375:155-158[CrossRef][Medline].
|
| 42.
|
Thiermann, A. B.,
A. L. Handsaker,
J. W. Foley,
F. H. White, and B. F. Kingscote.
1986.
Reclassification of North American leptospiral isolates belonging to serogroups Mini and Sejroe by restriction endonuclease analysis.
Am. J. Vet. Res.
47:61-66[Medline].
|
| 43.
|
Vasilakos, J. P.,
R. M. Smith,
S. J. Gibson,
J. M. Lindh,
L. K. Pederson,
M. J. Reiter,
M. H. Smith, and M. A. Tomai.
2000.
Adjuvant activities of immune response modifier R-848: comparison with CpG ODN.
Cell. Immunol.
204:64-74[CrossRef][Medline].
|
| 44.
|
Vincent, M. S.,
K. Roessner,
D. Lynch,
D. Wilson,
S. M. Cooper,
J. Tschopp,
L. H. Sigal, and R. C. Budd.
1996.
Apoptosis of Fashigh CD4+ synovial T cells by Borrelia-reactive Fas-ligandhigh  T cells in lyme arthritis.
J. Exp. Med.
184:2109-2117[Abstract/Free Full Text].
|
| 45.
|
Weynants, V.,
K. Walravens,
C. Didembourg,
P. Flanagan,
J. Godfroid, and J.-J. Letesson.
1998a.
Quantitative assessment by flow cytometry of T-lymphocytes producing antigen-specific -interferon in Brucella immune cattle.
Vet. Immunol. Immunopathol.
66:309-320[CrossRef][Medline].
|
| 46.
|
Weynants, V.,
D. Gilson,
A. Furger,
R. A. Collins,
P. Mertens,
X. DeBolle,
V. T. Heussler,
I. Roditi,
C. J. Howard,
A. E. Dobbelaere, and J.-J. Letesson.
1998b.
Production and characterisation of monoclonal antibodies specific for bovine interleukin-4.
Vet. Immunol. Immunopathol.
66:99-112[CrossRef][Medline].
|
| 47.
|
Woodard, L. F.,
N. M. Toone, and C. A. McLaughlin.
1980.
Comparison of muramyl dipeptide, trehalose dimycolate, and dimethyl dioctadecyl ammonium bromide as adjuvants in Brucella abortus 45/20 vaccines.
Infect. Immun.
30:409-412[Abstract/Free Full Text].
|
| 48.
|
Yip, H. C.,
A. Y. Karulin,
M. Tary-Lehmann,
M. D. Hesse,
H. Radeke,
P. S. Heeger,
R. P. Trezza,
F. P. Heinzel,
T. Forsthuber, and P. V. Lehmann.
1999.
Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response.
J. Immunol.
162:3942-3949[Abstract/Free Full Text].
|
Infection and Immunity, December 2001, p. 7550-7558, Vol. 69, No. 12
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.12.7550-7558.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Srikram, A., Wongratanacheewin, S., Puapairoj, A., Wuthiekanun, V., Sermswan, R. W.
(2008). Analyses of Vaccination Protocols for Leptospira interrogans Serovar Autumnalis in Hamsters. Am J Trop Med Hyg
79: 779-786
[Abstract]
[Full Text]
-
Vernel-Pauillac, F., Merien, F.
(2006). Proinflammatory and Immunomodulatory Cytokine mRNA Time Course Profiles in Hamsters Infected with a Virulent Variant of Leptospira interrogans. Infect. Immun.
74: 4172-4179
[Abstract]
[Full Text]
-
Palaniappan, R. U. M., McDonough, S. P., Divers, T. J., Chen, C.-S., Pan, M.-J., Matsumoto, M., Chang, Y.-F.
(2006). Immunoprotection of Recombinant Leptospiral Immunoglobulin-Like Protein A against Leptospira interrogans Serovar Pomona Infection. Infect. Immun.
74: 1745-1750
[Abstract]
[Full Text]
-
Branger, C., Chatrenet, B., Gauvrit, A., Aviat, F., Aubert, A., Bach, J. M., Andre-Fontaine, G.
(2005). Protection against Leptospira interrogans Sensu Lato Challenge by DNA Immunization with the Gene Encoding Hemolysin-Associated Protein 1. Infect. Immun.
73: 4062-4069
[Abstract]
[Full Text]
-
Rogers, A. N., VanBuren, D. G., Hedblom, E. E., Tilahun, M. E., Telfer, J. C., Baldwin, C. L.
(2005). {gamma}{delta} T Cell Function Varies with the Expressed WC1 Coreceptor. J. Immunol.
174: 3386-3393
[Abstract]
[Full Text]
-
Artiushin, S., Timoney, J. F., Nally, J., Verma, A.
(2004). Host-Inducible Immunogenic Sphingomyelinase-Like Protein, Lk73.5, of Leptospira interrogans. Infect. Immun.
72: 742-749
[Abstract]
[Full Text]
-
Klimpel, G. R., Matthias, M. A., Vinetz, J. M.
(2003). Leptospira interrogans Activation of Human Peripheral Blood Mononuclear Cells: Preferential Expansion of TCR{gamma}{delta}+ T Cells vs TCR{alpha}{beta}+ T Cells. J. Immunol.
171: 1447-1455
[Abstract]
[Full Text]
-
de Fost, M., Hartskeerl, R. A., Groenendijk, M. R., van der Poll, T.
(2003). Interleukin 12 in Part Regulates Gamma Interferon Release in Human Whole Blood Stimulated with Leptospira interrogans. CVI
10: 332-335
[Abstract]
[Full Text]
-
Naiman, B. M., Blumerman, S., Alt, D., Bolin, C. A., Brown, R., Zuerner, R., Baldwin, C. L.
(2002). Evaluation of Type 1 Immune Response in Naive and Vaccinated Animals following Challenge with Leptospira borgpetersenii Serovar Hardjo: Involvement of WC1+{gamma}{delta} and CD4 T Cells. Infect. Immun.
70: 6147-6157
[Abstract]
[Full Text]